<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000965</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 161</org_study_id>
    <nct_id>NCT00000965</nct_id>
  </id_info>
  <brief_title>The Effects of Zidovudine on the Blood of HIV-Infected Patients</brief_title>
  <official_title>Pharmacokinetics of Total Phosphorylated Zidovudine in Mononuclear Cells From HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To define the pharmacokinetic parameters (blood levels) of total phosphorylated zidovudine&#xD;
      (AZT) in peripheral blood mononuclear cells (PBMC) from HIV-infected patients.&#xD;
&#xD;
      Despite an understanding of the serum (or plasma) pharmacokinetics (blood levels) of AZT, a&#xD;
      therapeutic concentration range and optimal dosing interval have not yet been determined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite an understanding of the serum (or plasma) pharmacokinetics (blood levels) of AZT, a&#xD;
      therapeutic concentration range and optimal dosing interval have not yet been determined.&#xD;
&#xD;
      Three studies are planned on two separate patient groups. Group (1) Patients who have never&#xD;
      taken AZT start on a standard dose of AZT. Blood samples are taken hourly for an 8-hour&#xD;
      period on days 1 and 14. Other blood samples are taken on days 2, 4, and 8. Group (2)&#xD;
      Patients who have never taken AZT are given a standard dose for the first week, increasing&#xD;
      each week until week 5. Blood samples are taken at the end of each weekly treatment. After 4&#xD;
      weeks of standard treatment, patients in groups 1 and 2 return and receive a single morning&#xD;
      dose of oral AZT. Blood samples are taken immediately before dosing and at 1, 2, 4, 6, and 8&#xD;
      hours after dosing. After a 48-hour clearance period, patients return and resume dosing.&#xD;
      Blood samples are again taken over an 8-hour period. After 24 weeks of standard treatment,&#xD;
      the pharmacokinetic studies are repeated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">August 1993</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>20</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  FDA-approved anti-pneumocystis and antifungal prophylactic or suppressive regimens.&#xD;
&#xD;
          -  Acyclovir for up to 3 weeks intermittently.&#xD;
&#xD;
        Patients must:&#xD;
&#xD;
          -  Meet current guidelines for receiving prescription zidovudine.&#xD;
&#xD;
          -  Have written informed consent from both subject and parent or guardian if under 18. Be&#xD;
             capable of understanding and giving informed consent. Women and minorities are&#xD;
             actively encouraged to participate.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Malabsorption syndrome (3 or more loose stools/day for at least 4 weeks associated&#xD;
             with unintentional weight loss of greater than 10 percent of body weight).&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Probenecid or non-FDA approved investigational drugs.&#xD;
&#xD;
          -  Systemic chemotherapy.&#xD;
&#xD;
          -  Other antiviral agents, licensed or investigational, including ganciclovir, foscarnet,&#xD;
             ribavirin, didanosine (ddI), dideoxycytidine (ddC), and dideoxydidehydrothymidine&#xD;
             (D4T).&#xD;
&#xD;
        Chronic acyclovir.&#xD;
&#xD;
        -&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Active bacterial, fungal, or viral infection requiring systemic therapy not&#xD;
             specifically allowed.&#xD;
&#xD;
          -  Significant, chronic medical conditions that could impair compliance with study&#xD;
             treatment.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Systemic chemotherapy within previous 6 months.&#xD;
&#xD;
          -  Acyclovir within 30 days of study entry.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Unable to take oral medication reliably.&#xD;
&#xD;
          -  Alcohol or drug abuse that could impair compliance with study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>B Stretcher</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>P Frame</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>A Pesce</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>452670405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stretcher BN, Pesce AJ, Frame PT, Greenberg KA, Stein DS. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS. 1994 Jun;8(6):763-9. doi: 10.1097/00002030-199406000-00007.</citation>
    <PMID>8086134</PMID>
  </reference>
  <reference>
    <citation>Stretcher BN. Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Clin Pharmacokinet. 1995 Jul;29(1):46-65. doi: 10.2165/00003088-199529010-00006.</citation>
    <PMID>7586898</PMID>
  </reference>
  <reference>
    <citation>Stretcher BN, Pesce AJ, Frame PT, Stein DS. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1994 Jul;38(7):1541-7. doi: 10.1128/AAC.38.7.1541.</citation>
    <PMID>7979286</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>February 25, 2011</last_update_submitted>
  <last_update_submitted_qc>February 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2011</last_update_posted>
  <keyword>Leukocytes, Mononuclear</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Phosphorylation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

